Skip to main content
Premium Trial:

Request an Annual Quote

Suzhou Ribo Life Sciences Takes License to Life Tech siRNA Drug-delivery Technology

Premium

Life Technologies announced this week that it has signed a licensing agreement giving Suzhou Ribo Life Sciences the exclusive rights to use its Invivofectamine Rx delivery technology in the development and manufacturing of siRNA therapeutics in China.

Life Technologies said that it stands to receive milestones and royalties on the sale of products incorporating the technology. Additional terms of the arrangement were not disclosed.

"Adding Life's Invivofectamine Rx formulation technology into our development efforts will significantly increase our ability to bring new siRNA therapeutics to Chinese patients with unmet medical needs," Ribo CEO Zicai Liang said in a statement. "We look forward to bringing our first Invivofectamine Rx-based program targeting hepatitis B into the clinic in a relatively short period of time."

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.